The medical device company sprung from the $14 billion mega merger between two orthopedic powerhouses, Zimmer and Biomet, in 2015. Since then, the company has seen its CEO resign abruptly and as of July 2017, it seemed to struggle meeting financial projections.
Company Info
| CEO | Daniel P. Florin |
| CEO Title | Interim Chief Executive Officer & Director |
| Sector | Health Care |
| Industry | Medical Products and Equipment |
| HQ Location | Warsaw, IN |
| Website | www.zimmerbiomet.com |
| Years on Fortune 500 List | 2 |
| Employees | 18,500 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $7,684 |
| Profits ($M) | $305.9 |
| Assets ($M) | $26,684 |
| Total Stockholder Equity ($M) | $9,669 |
| Market Value — as of March 31, 2017 ($M) | $24,571 |
Profit Ratios
| Profit as % of Revenues | 4% |
| Profits as % of Assets | 1.1% |
| Profits as % of Stockholder Equity | 3.2% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 151 |
| EPS % Change (from 2015) | 96.1% |
| EPS % Change (5 year annual rate) | -17.8% |
| EPS % Change (10 year annual rate) | -7.8% |
Total Return
| Total Return to Investors (2016) | 1.4% |
| Total Return to Investors (5 year, annualized) | 15.1% |
| Total Return to Investors (10 year, annualized) | 3.2% |
